A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults

A stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate with/without adjuvant was evaluated in adults aged 65-85 years. RSVpreF vaccine candidates were well tolerated and elicited robust and persistent serum neutralizing responses; adjuvanted formulations did not further enhance responses. Background Respiratory syncytial virus (RSV) is an important cause of disease in older adults. We evaluated the safety and immunogenicity of a stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate with/without adjuvant in adults aged 65-85 years. Methods Primary cohort participants were equally randomized to 1 of 7 RSVpreF formulations: 60 mu g with either Al(OH)(3) or CpG/Al(OH)(3), 120 mu g with either Al(OH)(3) or CpG/Al(OH)(3), 240 mu g with either Al(OH)(3) or CpG/Al(OH)(3), 240 mu g unadjuvanted, or placebo, administered concomitantly with high-dose seasonal inactivated influenza vaccine (SIIV). Participants in the month 0,2 cohort were randomized to RSVpreF 240 mu g with CpG/Al(OH)(3) or placebo, administered at months 0 and 2. Results All RSVpreF vaccine candidates elicited robust and persistent serum neutralizing responses when administered alone or with SIIV. There was no notable difference in neutralizing response between the formulations, including those containing CpG. In the month 0,2 cohort, there was no booster effect of dose 2. SIIV responses were similar or slightly lower with concomitant administration of RSVpreF. Most systemic and local reactions were mild and more frequent after RSVpreF than placebo. Conclusions RSVpreF formulations were well tolerated and elicited robust neutralizing responses in older adults; however, CpG/Al(OH)(3) did not further enhance responses. Clinical Trials Registration . NCT03572062.

Automated summary

The stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate was well tolerated and elicited strong and persistent serum neutralizing responses in adults aged 65-85, with or without adjuvant. Adjuvanted formulations did not show additional enhancement of immune responses.